source
- FDA approves treatments for four rare diseases; Pfizer inks $2.6 billion China licensing deal for CAR‑T therapyThe U.S. Food and Drug Administration has granted approval for drugs targeting four distinct rare diseases, expanding therapeutic options for patients with limited treatment choices. In a separate…
- Congressional biotech panel cautions on rising China licensing dealsA bipartisan congressional commission that advises on U.S. biotech competitiveness is concluding its work with a focus on partnerships with Chinese firms. The panel highlighted the growing number…